It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its primary endpoint and multiple key secondary ...

In patients with active systemic lupus erythematosus unresponsive to conventional hydroxychloroquine-based therapy, adding mepacrine shows improved outcomes with few and mild side effects.

How would you treat a 30-year-old woman with systemic lupus erythematous (SLE) and lupus nephritis (LN) class 3 with new ...

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...

Please provide your email address to receive an email when new articles are posted on . Early mycophenolate mofetil in newly diagnosed SLE led to fewer severe flares and lower incidence of lupus ...

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease with a heterogeneous clinical presentation, ranging from mild cutaneous manifestations to severe organ damage. One of ...

An international team, led by Paul R. Fortin of Université Laval, has just identified three markers that would allow for establishing, right at the time of diagnosis, the risk of a lupus ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...